T20211211879
2022-09-05
15.8也不见高盛这**买一股，明显反向指标
【券商聚焦】高盛维持药明巨诺(02126)“买入”评级 指其上半年产品毛利率符预期
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":669698149,"tweetId":"669698149","gmtCreate":1662366288181,"gmtModify":1662366289413,"author":{"id":3567326116847906,"authorId":3567326116847906,"authorIdStr":"3567326116847906","name":"T20211211879","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>15.8也不见高盛这**买一股，明显反向指标</p></body></html>","htmlText":"<html><head></head><body><p>15.8也不见高盛这**买一股，明显反向指标</p></body></html>","text":"15.8也不见高盛这**买一股，明显反向指标","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/669698149","repostId":2264517092,"repostType":2,"repost":{"id":"2264517092","weMediaInfo":{"introduction":"凤凰网港股","home_visible":1,"media_name":"凤凰网港股","id":"1002821290","head_image":"https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817"},"pubTimestamp":1662001317,"share":"https://www.laohu8.com/m/news/2264517092?lang=&edition=full","pubTime":"2022-09-01 11:01","market":"us","language":"zh","title":"【券商聚焦】高盛维持药明巨诺(02126)“买入”评级 指其上半年产品毛利率符预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2264517092","media":"凤凰网港股","summary":"高盛发研报指，药明巨诺上半年收入6600万元，开具了77张倍诺达处方，完成64位患者的回输。据公司指引，预计2022年接受治疗的患者总数约为150名。期内，CAR-T产品CARVYKTI毛利率达35%，自2021财年以来增长了约5%。该行将2022-2024年毛利率预期下调35%/40%/45%；同时考虑到疫情影响研究进度，该行将3LMCL和1L/2L DLBCL的潜在批准时间表分别调整为2023年下半年与2024年上半年。目标价从21.83港元下调28%至15.81港元，维持“买入”评级。","content":"<html><body><p><a href=\"https://laohu8.com/S/GS\">高盛</a>发研报指，药明巨诺(02126)上半年收入6600万元（该行预期为5900万元），开具了77张倍诺达处方，完成64位患者的回输。据公司指引，预计2022年接受治疗的患者总数约为150名。期内，CAR-T产品CARVYKTI毛利率达35%，自2021财年以来增长了约5%。由于研发费用较低，总运营支出录得3.71亿元，低于该行4.81亿元预期。但随着公司开始增加对早期研发的关注，并从肿瘤学扩展到自身免疫疾病，预计未来研发或将增加。净亏损4.29亿元，主因未实现汇兑净亏损9100万元所致。</p><p>该行将2022-2024年毛利率预期下调35%/40%/45%；同时考虑到疫情影响研究进度，该行将3LMCL和1L/2L&nbsp;DLBCL的潜在批准时间表分别调整为2023年下半年与2024年上半年。目标价从21.83港元下调28%至15.81港元，维持“买入”评级。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【券商聚焦】高盛维持药明巨诺(02126)“买入”评级 指其上半年产品毛利率符预期</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【券商聚焦】高盛维持药明巨诺(02126)“买入”评级 指其上半年产品毛利率符预期\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1002821290\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/b6fb647077f1ce46dc341fc35c26e817);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">凤凰网港股 </p>\n<p class=\"h-time\">2022-09-01 11:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p><a href=\"https://laohu8.com/S/GS\">高盛</a>发研报指，药明巨诺(02126)上半年收入6600万元（该行预期为5900万元），开具了77张倍诺达处方，完成64位患者的回输。据公司指引，预计2022年接受治疗的患者总数约为150名。期内，CAR-T产品CARVYKTI毛利率达35%，自2021财年以来增长了约5%。由于研发费用较低，总运营支出录得3.71亿元，低于该行4.81亿元预期。但随着公司开始增加对早期研发的关注，并从肿瘤学扩展到自身免疫疾病，预计未来研发或将增加。净亏损4.29亿元，主因未实现汇兑净亏损9100万元所致。</p><p>该行将2022-2024年毛利率预期下调35%/40%/45%；同时考虑到疫情影响研究进度，该行将3LMCL和1L/2L&nbsp;DLBCL的潜在批准时间表分别调整为2023年下半年与2024年上半年。目标价从21.83港元下调28%至15.81港元，维持“买入”评级。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"02126":"药明巨诺-B"},"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=81b1e0529a4c4528dca0c964ed06c9e4","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2264517092","content_text":"高盛发研报指，药明巨诺(02126)上半年收入6600万元（该行预期为5900万元），开具了77张倍诺达处方，完成64位患者的回输。据公司指引，预计2022年接受治疗的患者总数约为150名。期内，CAR-T产品CARVYKTI毛利率达35%，自2021财年以来增长了约5%。由于研发费用较低，总运营支出录得3.71亿元，低于该行4.81亿元预期。但随着公司开始增加对早期研发的关注，并从肿瘤学扩展到自身免疫疾病，预计未来研发或将增加。净亏损4.29亿元，主因未实现汇兑净亏损9100万元所致。该行将2022-2024年毛利率预期下调35%/40%/45%；同时考虑到疫情影响研究进度，该行将3LMCL和1L/2L DLBCL的潜在批准时间表分别调整为2023年下半年与2024年上半年。目标价从21.83港元下调28%至15.81港元，维持“买入”评级。","news_type":1},"isVote":1,"tweetType":1,"viewCount":835,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["GS"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":37,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/669698149"}
精彩评论